Allosteric regulation is a fundamental mechanism in enzyme function, enabling dynamic modulation of activity through ligand binding at sites distal to the active site.
Understanding the dynamic conformations of proteins is important for rational drug discovery. While molecular dynamics (MD) simulation is the primary tool for this purpose, it is both resource- and time-consuming. Recent advances in deep learning offer an attractive alternative by generating conformational ensembles directly from protein sequences. However, the scope of applying such models to protein dynamics studies remains underexplored. Here, we tested the performance of a representative model, BioEmu, across several tasks related to protein dynamics. Our results show that BioEmu can not only generate multiple conformations but also effectively reproduce fundamental properties including residue flexibility, motion correlations, and local residue contacts. However, it fails to predict a mutation-induced shift in conformational distribution and exhibits a preference for higher-energy conformations over lower-energy ones in some cases, indicating that it does not reproduce a right Boltzmann-weighted ensemble. Furthermore, the BioEmu-generated conformations provide only limited improvement in ensemble docking. These findings delineate the current capabilities and limitations of sequence-based generative models for conformational sampling. Also, they highlight several directions for future development—that further energy-based fine-tuning is needed for tasks related to conformational distributions and atom-level generative model is required to study the intermolecular relationship.
Src homology 2 (SH2) domain-containing phosphatase 2 (SHP2) is a key regulator in cellular signaling pathways because its dysregulation has been implicated in various pathological conditions, including cancers and developmental disorders. Despite its importance, the molecular basis of SHP2’s regulatory mechanism remains poorly understood, hindering the development of effective targeted therapies. In this study, we utilized the high-specificity monobody Mb11 to investigate its interaction with the SHP2 phosphatase domain (PTP) using multiple replica molecular dynamics simulations. Our analyses elucidate the precise mechanisms through which Mb11 achieves selective recognition and stabilization of the SHP2-PTP domain, identifying key residues and interaction networks essential for its high binding specificity and regulatory dynamics. Furthermore, the study highlights the pivotal role of residue C459 in preserving the structural integrity and functional coherence of the complex, acting as a central node within the interaction network and underpinning its stability and efficiency. These findings have significantly advanced the understanding of the mechanisms underlying SHP2’s involvement in disease-related signaling and pathology while simultaneously paving the way for the rational design of targeted inhibitors, offering significant implications for therapeutic strategies in SHP2-associated diseases and contributing to the broader scope of precision medicine.